Migräne-Kranit (Phenazone)

Phenazone works by non‑selectively inhibiting cyclooxygenase enzymes (COX‑1 and COX‑2). This inhibition reduces the production of prostaglandins, which are mediators that amplify pain and inflammation. Lower prostaglandin levels lead to decreased pain signalling and provide analgesic effect.

The appropriate dose of Migräne‑Kranit is determined by the prescribing healthcare professional based on the individual patient's condition, age, and response to therapy. Patients should follow the prescriber’s instructions and not alter the dose without medical advice.

Safety data for phenazone during pregnancy and lactation are limited. It should only be used if the potential benefit justifies any possible risk to the fetus or infant. Healthcare providers will assess the risk‑benefit profile before prescribing to pregnant or nursing women.

To order Migräne‑Kranit, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, and will request trade or institutional credentials before providing pricing, availability, shipping details and any necessary import documentation.

Phenazone belongs to the pyrazolone class, which differs from traditional NSAIDs such as ibuprofen or naproxen. While all provide analgesia, phenazone’s non‑selective COX inhibition may produce a faster onset when given rectally, but it also carries a distinct safety profile that includes rare blood‑related adverse events.

Store Migräne‑Kranit at ambient temperature, preferably below 25 °C. Keep the product in its original packaging, protect it from moisture and direct sunlight, and ensure the rectal dosage form remains intact until use.

Migräne‑Kranit is administered rectally. The appropriate dose is inserted into the rectum using the supplied applicator or as directed by a healthcare professional, allowing the medication to be absorbed through the rectal mucosa for rapid systemic effect.

Serious risks include aplastic anemia, severe allergic reactions such as anaphylaxis, and hepatotoxicity. Patients should be monitored for signs of unexplained fatigue, bleeding, rash, or liver dysfunction, and medical attention should be sought immediately if these occur.

Migräne‑Kranit should be avoided in individuals with known hypersensitivity to phenazone or other pyrazolones, those with active gastrointestinal ulceration, severe hepatic or renal impairment, and patients with a history of bone‑marrow disorders unless specifically directed by a physician.